Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
As of close of business last night, Xilio Therapeutics Inc’s stock clocked out at $0.8, down -0.79% from its previous closing price of $0.81. In other words, the price has decreased by -$0.79 from its previous closing price. On the day, 2.69 million shares were traded. XLO stock price reached its highest trading level at $0.8989 during the session, while it also had its lowest trading level at $0.7745.
Ratios:
To gain a deeper understanding of XLO’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.32 and its Current Ratio is at 2.32. In the meantime, Its Debt-to-Equity ratio is 1.07 whereas as Long-Term Debt/Eq ratio is at 0.89.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Leerink Partners on August 06, 2025, initiated with a Outperform rating and assigned the stock a target price of $2.
On December 21, 2022, Chardan Capital Markets started tracking the stock assigning a Buy rating and target price of $7.
On January 10, 2022, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $36.H.C. Wainwright initiated its Buy rating on January 10, 2022, with a $36 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jun 16 ’25 when Shannon James Samuel bought 45,000 shares for $0.69 per share. The transaction valued at 30,870 led to the insider holds 45,000 shares of the business.
Shannon James Samuel bought 25,000 shares of XLO for $17,215 on Jun 17 ’25. The Director now owns 70,000 shares after completing the transaction at $0.69 per share. On Jun 16 ’25, another insider, Russo Rene, who serves as the PRESIDENT AND CEO of the company, bought 36,289 shares for $0.68 each. As a result, the insider paid 24,680 and bolstered with 281,172 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, XLO now has a Market Capitalization of 41649796 and an Enterprise Value of -72336088. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.78 while its Price-to-Book (P/B) ratio in mrq is 5.89. Its current Enterprise Value per Revenue stands at -4.822 whereas that against EBITDA is 1.315.
Stock Price History:
The Beta on a monthly basis for XLO is -0.05, which has changed by -0.39090908 over the last 52 weeks, in comparison to a change of 0.19088471 over the same period for the S&P500. Over the past 52 weeks, XLO has reached a high of $1.70, while it has fallen to a 52-week low of $0.62. The 50-Day Moving Average of the stock is 5.15%, while the 200-Day Moving Average is calculated to be 3.49%.
Shares Statistics:
It appears that XLO traded 606.80K shares on average per day over the past three months and 761200 shares per day over the past ten days. A total of 51.83M shares are outstanding, with a floating share count of 18.37M. Insiders hold about 64.56% of the company’s shares, while institutions hold 11.55% stake in the company. Shares short for XLO as of 1760486400 were 5251586 with a Short Ratio of 8.65, compared to 1757894400 on 4923762. Therefore, it implies a Short% of Shares Outstanding of 5251586 and a Short% of Float of 14.71.
Earnings Estimates
Xilio Therapeutics Inc (XLO) is presently subject to a detailed evaluation by 2.0 analysts, each offering their unique perspectives on its market standing.The consensus estimate for the next quarter is -$0.1, with high estimates of -$0.08 and low estimates of -$0.12.
Analysts are recommending an EPS of between -$0.44 and -$0.46 for the fiscal current year, implying an average EPS of -$0.45. EPS for the following year is -$0.31, with 2.0 analysts recommending between -$0.18 and -$0.45.
Revenue Estimates
In. The current quarter, 2 analysts expect revenue to total $18.64M. It ranges from a high estimate of $26.67M to a low estimate of $10.6M. As of. The current estimate, Xilio Therapeutics Inc’s year-ago sales were $2.26MFor the next quarter, 2 analysts are estimating revenue of $9.28M. There is a high estimate of $10.6M for the next quarter, whereas the lowest estimate is $7.96M.
A total of 2 analysts have provided revenue estimates for XLO’s current fiscal year. The highest revenue estimate was $45.65M, while the lowest revenue estimate was $32.2M, resulting in an average revenue estimate of $38.92M. In the same quarter a year ago, actual revenue was $6.34MBased on 2 analysts’ estimates, the company’s revenue will be $56.27M in the next fiscal year. The high estimate is $81.75M and the low estimate is $30.8M.
